Free Trial
NASDAQ:HEPA

Hepion Pharmaceuticals Q2 2026 Earnings Results & Report

Hepion Pharmaceuticals logo
$0.09 -0.02 (-20.95%)
As of 02:09 PM Eastern

Hepion Pharmaceuticals beat analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.08 versus the -$200.00 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Hepion Pharmaceuticals EPS Results

Actual EPS
-$0.08
Consensus EPS
-$200.00
Beat/Miss
Beat by +$199.92
One Year Ago EPS
N/A

Hepion Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Hepion Pharmaceuticals' Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules

Earnings Documents

Hepion Pharmaceuticals Q2 2026 Earnings FAQ

Hepion Pharmaceuticals (NASDAQ:HEPA) reported earnings of -$0.08 per share for Q2 2026, beating the consensus estimate of -$200.00. The report was announced on Thursday, August 13, 2026.

Hepion Pharmaceuticals' next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Hepion Pharmaceuticals on the company's earnings history page.

Hepion Pharmaceuticals Earnings Headlines

I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
See More Hepion Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hepion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hepion Pharmaceuticals and other key companies, straight to your email.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals (NASDAQ:HEPA) (NASDAQ: HEPA) is a clinical-stage biopharmaceutical company focused on developing therapies for chronic liver diseases. The company’s research has centered on conditions including metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), chronic hepatitis B, and other diseases involving liver fibrosis and inflammation.

Hepion’s lead investigational product, rencofilstat (formerly known as CRV431), is an oral cyclophilin inhibitor designed to address biological pathways associated with liver disease progression. The compound has been evaluated for potential applications in MASH and chronic hepatitis B, although it remains an investigational therapy and is not approved for commercial use.

The company was formerly known as ContraVir Pharmaceuticals and adopted the Hepion Pharmaceuticals name in 2019. Its operations have primarily focused on research and clinical development rather than the sale of marketed products, with development activities conducted through clinical and research programs intended to support future regulatory approval.

View Hepion Pharmaceuticals Profile